FluoroPharma Medical of Montclair, New Jersey, is committed to the discovery, development, and commercialization novel molecular positron emission tomography (PET) agents for the cardiovascular, oncology and neurology arenas. The Company’s broad technology platform was developed in conjunction with leading scientists from Massachusetts General Hospital and Harvard Medical School. Our initial focus is the development of breakthrough PET imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries.